Science Based Targets initiative (SBTi) validates EUROAPI’s near-term climate targets

Core Insights - EUROAPI's near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi), aligning with the Paris Agreement to limit global warming to 1.5°C above pre-industrial levels [1][2] - The company commits to a 42% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2030 from a 2022 base year, and a 25% reduction in absolute Scope 3 GHG emissions in the same timeframe [1][5] Environmental Performance - EUROAPI has achieved measurable improvements in key environmental indicators between 2022 and 2024, including a 28% reduction in waste, a 14% reduction in solvent use, and a 12% reduction in energy consumption [2] - The company eliminated nearly 180,000 tons of CO2 equivalent during this period, equivalent to the annual GHG emissions of a city with approximately 20,000 inhabitants [2] - 100% of the electricity purchased by EUROAPI now comes from renewable sources, and the product carbon footprint is available for more than 70 active pharmaceutical ingredients (APIs) [2] Company Overview - EUROAPI focuses on reinventing active ingredient solutions to sustainably meet global customer and patient needs, with a portfolio of approximately 200 products [3] - The company operates five manufacturing sites in Europe and supplies customers in over 80 countries, emphasizing high-quality API manufacturing [4]